$IMRX

Immuneering Corp

Immuneering is a clinical-stage oncology company developing oral small-molecule cancer medicines called Deep Cyclic Inhibitors. Its drug candidates are designed to disrupt cancer signaling pathways, including the MAPK pathway. The lead candidate, atebimetinib, is an oral, once-daily MEK inhibitor being studied for advanced solid tumors, including pancreatic cancer. Immuneering is initiating a Phase 3 trial evaluating it with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer. Its second clinical-stage candidate, envometinib, is an allosteric MEK inhibitor; the company has paused its internal development and is pursuing partnership opportunities. Immuneering also has earlier-stage discovery programs targeting other cancer-signaling pathways. The company uses bioinformatics and proprietary 3D tumor models to guide drug discovery and development. It previously provided translational bioinformatics services to pharmaceutical and biotechnology companies, but has since ceased that business. Immuneering is headquartered in Cambridge, Massachusetts.

4
0
0
$90K
—
Gengos Andrew
0%
See all $IMRX insider activity →

IMRX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning IMRX (Immuneering Corp). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.

Recent IMRX coverage spans technology, financial news and earnings.

In the last 30 days, IMRX insiders filed 1 SEC Form 4 transaction — 1 purchase ($90K) and no sales. The most active reporter was Gengos Andrew, Chief Financial Officer, with 1 filing.

What's driving IMRX

  • Positive trial data may boost investor confidence and drive short-term price appreciation.

    rttnews.com · Nov 18, 2026

  • Preclinical efficacy plus a stated Phase 2 plan can improve perceived probability of clinical success, but it is not yet validated by human ATC outcomes.

    tradingview.com · Nov 18, 2026

  • Insider open-market buying can be read as mild positive sentiment, but the disclosure is unlikely to drive a large repricing by itself.

    SEC EDGAR · Nov 16, 2026

  • Insider open-market buying may provide modest sentiment support, but it is not a fundamental catalyst by itself.

    quantisnow.com · Nov 16, 2026

  • The trial announcement adds a new development milestone for Immuneering, likely prompting short‑term buying interest.

    finance.yahoo.com · Nov 12, 2026

AlphAI scores every news story that mentions IMRX with an AI model for sentiment and relevance, and aggregates insider trades from Immuneering Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IMRX

Score
$IMRXLowExec change· appointed

Immuneering Corp (IMRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Immuneering Corp (IMRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 9, 2026, the Board of Directors (the "Board") of Immuneering Corporation (the “Company”) appointed Grant C. Bo

Related tickers